Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

Percutaneous Left Atrial Appendage (LAA) Closure Therapy

Percutaneous Left Atrial Appendage (LAA) Closure Device  MP9499

Covered Service: Yes—when meets criteria below

Prior Authorization Required: Yes—as shown below

Additional Information: None

Prevea360 Health Plan Medical Policy:

1.0 Left Atrial Appendage (LAA) closure device requires prior authorization through the Health Services Division and is approved for patients with non-valvular atrial fibrillation who are at increased risk of stroke/systemic embolism, when ALL of the following criteria are met:

   1.1 Nonvalvular sustained or paroxysmal atrial fibrillation;
   1.2 Elevated risk of embolic stroke (e.g. CHAD2DS2-VASc score ≥ 2, ATRIA score ≥ 6; AND
   1.3 Medical management (anticoagulation) not preferred due to 1 or more of the following:
       1.3.1 Thromboembolism while on oral anticoagulant (e.g. while on therapeutic dosage, or INR in therapeutic range);
       1.3.2 Elevated risk of bleeding on oral anticoagulant (e.g. HAS-BLED score of 3 or more);
       1.3.3 Other contraindications to long-term anticoagulation;
       1.3.4 Patient unable or unwilling to use long-term anticoagulation
   1.4 Short-term (months) post-procedural antithrombotic treatment and long-term aspirin is not contraindicated and is acceptable to patient; AND
   1.5 Cardiac anatomy is amenable to procedure
   1.6 The use of the left atrial appendage closure devices for other indications, or to use a device other than the Watchman is considered experimental and investigational, and is therefore not medically necessary.
Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member’s benefit certificate or policy and to applicable state and/or federal laws.

CHADS2 and CHA2DS2-VASc Risk Stratification Scores for Nonvalvular Atrial Fibrillation

<table>
<thead>
<tr>
<th>Scores for CHADS2</th>
<th>Scores for CHA2DS2-VASc</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHADS2 acronym</strong></td>
<td><strong>CHA2DS2-VASc acronym</strong></td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td>Congestive Heart Failure</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Age ≥ 75 years</td>
<td>Age ≥ 75 years</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>Prior Stroke/TIA/TE</td>
<td>Prior Stroke/TIA/TE</td>
</tr>
<tr>
<td><strong>Maximum score</strong></td>
<td><strong>Vascular disease (prior MI, PAD, or aortic plaque)</strong></td>
</tr>
<tr>
<td></td>
<td>Age 65 to 74 years</td>
</tr>
<tr>
<td></td>
<td>Sex category (i.e., female sex)</td>
</tr>
<tr>
<td></td>
<td><strong>Maximum score</strong></td>
</tr>
</tbody>
</table>

**Committee/Source**

**Originated:** Medical Policy Committee/Quality and Care Management Division  
**Date(s):** August 16, 2017

**Revised:** Medical Policy Committee/Health Services Division  
**Date(s):** August 15, 2018  
Medical Policy Committee/Health Services Division  
**Date(s):** July 17, 2019

**Reviewed:** Medical Policy Committee/Health Services Division  
**Date(s):** August 15, 2018  
Medical Policy Committee/Health Services Division  
**Date(s):** July 17, 2019

**Published/Effective:** 12/01/2019